Context Therapeutics Inc. has received FDA clearance of its IND application for CTIM-76, a Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody.
Alligator Bioscience AB reported that Orion Corp. has selected the lead bispecific antibodies from the companies’ second development program, and is exercising its option to develop these molecules under the existing 2021 research collaboration and license agreement.
Epidermal growth factor receptor (EGFR) is widely expressed among multiple cancer types, but patients often develop resistance to EGFR tyrosine kinase inhibitors (TKIs), which may be accompanied by increased expression of CD70.
A research team at University of California, Los Angeles (UCLA), funded by Cancervax Inc., has created a promising new bispecific antibody vaccine for treating recurrent Ewing sarcoma.
The overexpression of transferrin receptor 1 (TfR1) has been reported in several cancer types but is also expressed in normal cell types such as erythroblasts. On the other hand, epidermal growth factor receptor (EGFR) is highly expressed in epithelial carcinomas.
Researchers from Beigene (Beijing) Co. Ltd. have disclosed preclinical data for BGB-B167, a first-in-class immunoglobulin G (IgG)-based bispecific antibody (bsAb) targeting 4-1BB and CEA, being developed for the treatment of advanced or metastatic solid tumors.
It has been previously demonstrated that B7-H3 and EGFR are co-expressed in multiple solid tumors. At the ongoing AACR meeting in San Diego, researchers from Innovent Biologics Inc. presented preclinical data for their bispecific antibody (bsAb), IBI-334, against B7-H3 and EGFR.
Aethon Therapeutics Inc. has entered into a collaboration agreement with Revolution Medicines Inc. under which Aethon will use its Hapimmune platform to discover novel bispecific antibodies to mount an immune attack directed towards cancer cells hit by Revolution Medicines’ RAS(ON) inhibitors.
Context Therapeutics Inc. has submitted an IND application to the FDA to begin a first-in-human phase I study of CTIM-76 in patients with claudin 6 (CLDN6)-positive gynecologic and testicular cancers.
RSS
